H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Acorda Therapeutics (NASDAQ: ACOR) today and set a price target of $28. The company’s shares closed on Friday at $17.25, close to its 52-week low of $15.60.
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.3% and a 42.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Acorda Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $25.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.35 and a one-year low of $15.60. Currently, Acorda Therapeutics has an average volume of 590.9K.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
Read More on ACOR:
